| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Aug 11, 2020Completed treatment phase of pivotal EMERGE™ Phase 3 efficacy trial of STS101 as planned and remain on track to report top-line results in late September or early October 2020
South San Francisco, CA, August 11, 2020 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today summarized recent business progress and reported...
-
Aug 6, 2020ASCEND results expected to support STS101 NDA filing in Q4 2021
South San Francisco, CA, August 6, 2020 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today announced the initiation of patient enrollment in the...
-
Jul 7, 2020
South San Francisco, CA, July 7, 2020 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today announced that it has appointed biopharmaceutical industry...
-
Jun 11, 2020Meeting Launch date is Saturday, June 13th 2020 at 9:00am (PT)
South San Francisco, CA, June 11, 2020 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that two poster presentations supporting the...
-
Jun 1, 2020More than 1,140 patients randomized and topline results expected in second half 2020
South San Francisco, CA, June 1, 2020 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today reported completion of enrollment and randomization in its...